echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Innovent IBI362 clinical research in Chinese overweight or obese subjects published in the Lancet

    Innovent IBI362 clinical research in Chinese overweight or obese subjects published in the Lancet

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Cinda Biopharmaceuticals announced that the glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist IBI362 has been randomly selected among overweight or obese Chinese subjects.


    https://doi.


    China is the country with the largest number of obese people in the world, and it is showing a gradual upward trend


    IBI362 (LY3305677) is an innovative oxyntomodulin compound (OXM3) jointly promoted by Innovent Biopharmaceuticals and Eli Lilly.


    The results of clinical studies showed that each dose group of IBI362 improved in waist circumference, body mass index, blood pressure, cholesterol and triglyceride levels, and was well tolerated in overweight or obese Chinese subjects, and had significant weight loss effects.


    In the future, it is expected that IBI362 as a multi-target innovative drug in the subsequent phase II clinical studies in overweight/obese subjects will show even more surprising results


    Reference materials:

    [1]https://mp.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.